Nicotine Replacement Therapy Assignment Discussion

Nicotine Replacement Therapy Assignment Discussion

oe is a 68-year-old Caucasian male who presents for assistance with tobacco cessation. He began smoking when he was 12 years old. He smoked 2 packs per day until last year when he began reducing the number of cigarettes he smokes per day. He is currently at 8 cigarettes per day. He smokes when he gets up in the morning, with coffee, after breakfast, midmorning, after lunch, midafternoon, after supper, and before bed. He states that the cigarettes help him focus. He describes that abrupt cessation creates increased craving, irritability, increased hunger, and anxiety. Nicotine Replacement Therapy Assignment Discussion

ORDER A PLAGIARISM-FREE PAPER HERE

Select a Nicotine replacement therapy or medication that is used for nicotine dependence. Please include the available evidence and treatment guidelines. Share the mechanism of action of this medication and hints for monitoring, side effects, and drug interactions, including interactions with CAM. Identify an additional (possibly off-labeled) use of the medication not related to depression or psychosis. Include the name of the medication in the subject line so that the medications can be followed. Include references using APA format. Nicotine Replacement Therapy Assignment Discussion

Typically, therapies to help people break their cigarette habits include using nicotine replacement therapy or medicines. To help people quit smoking, nicotine replacement treatments use products like gum and skin patches to release nicotine into the body gradually. Zyban and Chantix are the two most often recommended drugs used to assist smokers stop. I would prescribe Chantix for this individual. One of the most recent pharmaceutical interventions, Chantix, was designed specifically to aid smokers in giving up the habit (Burke et al., 2016). The nicotine patch is one of the drugs known to interact with Chantix, which may increase the risk of side effects. Chantix therapy should last for 12 weeks. Those who can quit smoking after 12 weeks of therapy with Chantix are encouraged to continue using the medication for another 12 weeks to improve their chances of being smoke-free permanently (Singh & Saadabadi, 2021)Nicotine Replacement Therapy Assignment Discussion. Individuals above the age of 17 should take 0.5 milligrams (mg) once a day on days 1 through 3, 0.5 mg twice daily on days 4 through 7, and 1 mg twice daily on days eight until the conclusion of therapy (Burke et al., 2016).

The nicotinic acetylcholine receptor 42 is the site of the highest varenicline binding affinity. Hence, it is hypothesized that varenicline’s effectiveness in helping people quit smoking is due to its action at the 42 sub-types of the nicotinic receptors, where its binding creates partial agonist activity while inhibiting the binding of nicotine to these receptors (Burke et al., 2016). To a lesser extent than nicotine, varenicline activates nicotinic acetylcholine receptors via binding to these proteins. Inhibiting 42 receptor activation and dopaminergic system stimulation in the central nervous system (CNS) mesolimbic regions, varenicline blocks the neuronal process thought to underlie the reinforcement and reward experienced by addicts. Although it interacts with several nicotinic receptors, varenicline has a particularly strong affinity for alpha4 beta2. It lessens the severity of withdrawal and cravings that accompany trying to quit. Thanks to its partial agonism, varenicline significantly reduces the activation of the mesolimbic dopamine pathway associated with nicotine addiction (Singh & Saadabadi, 2021). To yet, varenicline has no known antidotes. Patients should stop using varenicline promptly if they have any major side effects, such as mental problems or a skin hypersensitivity response. This medication may also alleviate dry eye syndrome symptoms (Vollmer et al., 2021)Nicotine Replacement Therapy Assignment Discussion.

References

Burke, M. V., Hays, J. T., & Ebbert, J. O. (2016). Varenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherence. Patient preference and adherence, 10, 435. https://doi.org/10.2147%2FPPA.S83469

Singh, D., & Saadabadi, A. (2021). Varenicline. In StatPearls [Internet]. StatPearls publishing. https://www.ncbi.nlm.nih.gov/books/NBK534846/

ORDER TODAY

Vollmer, P. M., Aune, C. A., & Kabat, K. G. (2021, June). Varenicline nasal spray (OC-01) for the treatment of dry eye disease: the ONSET-2 study. In Poster presented at: New Technologies and Treatments in Eye Care Summer 2021 Conference. https://www.researchgate.net/profile/Alan-Kabat/publication/350042925_Varenicline_Nasal_Spray_OC-01_for_the_Treatment_of_Dry_Eye_Disease_The_ONSET-2_Study/links/6063574892851cd8ce7ac31e/Varenicline-Nasal-Spray-OC-01-for-the-Treatment-of-Dry-Eye-Disease-The-ONSET-2-Study.pdf Nicotine Replacement Therapy Assignment Discussion